Enovis (ENOV) Short-term Investments (2017 - 2022)

Enovis (ENOV) reported Short-term Investments of $200.3 million for Q3 2022, down 23.88% quarter-over-quarter from $263.1 million in Q3 2022.

Enovis (ENOV) Short-term Investments (2017 - 2022) Analysis & Trends

Enovis (ENOV) has 2 years of Short-term Investments data on file, last reported at $200.3 million in Q3 2022.

Short-term Investments for Q3 2022 came in at $200.3 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2022 was $200.3 million (changed N/A YoY), and the FY2017 annual result was $149.6 million, changed N/A from the prior year.
Short-term Investments slipped to $200.3 million in Q3 2022 per ENOV's latest filing, from $263.1 million in the prior quarter.
Over five years, Short-term Investments peaked at $263.1 million in Q3 2022 and troughed at $200.3 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn
10	Enovis	1.24 Bn	1.21 Bn	365.49 Mn

Download Data